The reported EGFR mutation rate in patients with lung adenocarcinoma varies widely between different populations worldwide, ranging from 10 to 20% in European and North American cohorts [5, 6, 13–23] to more than 50% in Asian populations [24, 25]. This evidence concerns the gene EGFR and lung adenocarcinoma.